Eyeball Injections: Procedure, Side Effects & Recovery

Few medical treatments provoke as much curiosity—and apprehension—as the idea of an injection into the eye. Yet for thousands of Australians each year, intravitreal injections (commonly referred to as eyeball injections) represent a pivotal step in protecting or restoring sight threatened by serious retinal conditions. If you or someone you care about has been recommended this treatment, it’s natural to have questions about what’s involved, whether it will be uncomfortable, and how safe it really is.

Eyeball injections are now a cornerstone in managing conditions like age-related macular degeneration, diabetic eye disease, and retinal vein occlusion. These procedures deliver medication directly to the back of the eye, targeting the source of vision loss with remarkable precision. While the thought of an eye injection may sound daunting, advances in technique and patient care mean that the process is far more straightforward—and less intimidating—than many expect.

This article guides you through every stage of the intravitreal injection journey: from understanding why these injections are used and which eye diseases they treat, to what actually happens during the procedure, the types of medication involved, possible side effects, and what to expect during recovery. You’ll also find answers to common concerns, practical aftercare tips, and an overview of treatment costs in Australia. With clear explanations and a focus on patient comfort, our aim is to help you feel informed and confident as you consider your options for preserving your vision.

What Are Intravitreal (Eyeball) Injections?

Intravitreal injections are treatments in which medication is delivered directly into the eye’s vitreous cavity, the jelly-like space between the lens and the retina. By placing drugs into this part of the eye, doctors can target retinal conditions such as macular degeneration, diabetic retinopathy and vein occlusions more effectively than with eye drops or systemic medicines.

Unlike sub-Tenon or periocular injections that release medication around the eye, intravitreal injections pass the needle through the pars plana—an area of the white sclera—to reach the vitreous gel. This direct route helps to overcome anatomical barriers that can limit drug delivery when using other approaches.

To see how this works, it helps to picture a cross-section of the eye:

• Cornea: the clear front window that focuses light.
• Anterior chamber: the fluid-filled space just behind the cornea.
• Lens: sits in front of the vitreous cavity and fine-tunes focus.
• Vitreous cavity: the gel-filled chamber where the needle deposits medication.
• Retina: the light-sensitive layer at the back that sends images to the brain.

By bypassing the eye’s natural defences and delivering medicine straight into the vitreous, treatments reach the retina at concentrations high enough to control swelling, halt abnormal blood vessel growth or fight infection—usually with a single 0.05 mL injection.

Definition and Key Concepts

Intravitreal injections enter through the pars plana, a thin region of the sclera located roughly 3–4 mm behind the limbus (the junction between cornea and white of the eye). The needle passes through this zone because it contains no critical blood vessels or retina, making it safer and minimises discomfort.

Intravitreal injections differ from other intraocular procedures. Sub-Tenon injections sit in the space between the sclera and Tenon’s capsule, while periocular injections deliver drugs around the eye’s exterior. Only intravitreal injections place medicine directly into the vitreous cavity, ensuring the highest possible concentration at the retina.

Why Direct Delivery Matters

The eye is protected by multiple barriers—tear film, corneal epithelium and the blood–retinal barrier—which control what enters or leaves ocular tissue. While these defences ward off harmful substances, they also limit the effectiveness of topical or oral treatments.

Intravitreal therapy dates back to early antibiotic injections in the 1940s for endophthalmitis. The advent of anti-vascular endothelial growth factor (anti-VEGF) agents in the 2000s transformed care for wet age-related macular degeneration. By overcoming delivery barriers, intravitreal injections now form the backbone of modern retinal disease management.

Common Indications for Eyeball Injections

Intravitreal injections are a versatile treatment option for a variety of sight-threatening retinal conditions. By delivering medication directly to the back of the eye, these injections tackle the root causes of vision loss—whether that’s abnormal blood vessel growth, fluid leakage, inflammation or infection. Below is a quick overview of the main conditions treated with eyeball injections, the type of therapy used and representative examples.

Wet Age-Related Macular Degeneration (AMD)

Wet AMD arises when new, fragile blood vessels grow beneath the retina and leak fluid or blood. This neovascularisation disrupts central vision, making tasks such as reading or recognising faces difficult. Anti-VEGF agents—drugs that block vascular endothelial growth factor—halt vessel growth and reduce leakage. In Australia, TGA-approved therapies include Byooviz, Eylea (aflibercept) and Lucentis (ranibizumab), Vabysmo. Treatment typically begins with monthly injections, gradually extending the interval as the retina stabilises.

Diabetic Retinopathy and Diabetic Macular Oedema

Long-term high blood sugar in diabetes damages tiny retinal vessels, causing microaneurysms, bleeding and fluid leakage into the macula (centre of the retina). When fluid accumulates, it’s known as diabetic macular oedema (DME). In non-proliferative diabetic retinopathy, vessels weaken but new vessel growth hasn’t yet started; in proliferative stages, abnormal vessels appear and increase the risk of bleeding or retinal detachment. Intravitreal anti-VEGF injections reduce swelling and improve vision, while steroid injections (for example, dexamethasone implants) may be used when inflammation plays a bigger role.

Retinal Vein Occlusion (BRVO & CRVO)

Retinal vein occlusion occurs when a clot blocks blood flow in a branch (BRVO) or the central retinal vein (CRVO). Pressure builds up behind the blockage, leading to fluid leakage and macular oedema. Anti-VEGF injections help by shrinking those leaky vessels, and steroids can calm associated inflammation. Most patients require a series of injections at regular intervals until fluid resolves and vision stabilises.

Uveitis and Intraocular Infections

Uveitis—an inflammation of the eye’s middle layer—can be driven by autoimmune conditions, infections or trauma. Intraocular infections (endophthalmitis, retinitis) may arise from bacteria, fungi or viruses. Steroid injections (like triamcinolone) control inflammation in non-infectious uveitis, whereas antibiotics (vancomycin, ceftazidime) and antivirals (ganciclovir) are injected directly into the vitreous to fight pathogens. Prompt treatment is essential to prevent permanent vision loss.

Other Uses (Pathologic Myopia, Gas Tamponade)

Pathologic myopia can induce abnormal vessel growth under the retina (choroidal neovascularisation), treated with anti-VEGF drugs—much like wet AMD. In cases of retinal detachment, small gas bubbles (sulphur hexafluoride, SF6; perfluoropropane, C3F8) are injected into the vitreous cavity to gently press the retina back into place. Patients follow strict head-positioning guidelines so the bubble remains in contact with the detachment site during healing.

Types of Medications Delivered

Intravitreal injections can carry a variety of substances, each tailored to tackle a specific retinal problem—whether that’s abnormal vessel growth, inflammation, infection or mechanical support after a detachment. The table below provides a quick reference to the main drug classes, examples and typical dosing schedules.

Anti-VEGF Agents

Vascular endothelial growth factor (VEGF) drives new, leaky blood vessel formation and fluid build-up in conditions such as wet AMD, diabetic macular oedema and retinal vein occlusions. Anti-VEGF drugs bind to VEGF molecules, blocking their action and thereby shrinking abnormal vessels and reducing swelling. Most treatment plans start with monthly injections for three to six doses (the “loading phase”), before moving to a treat-and-extend or pro re nata (PRN) schedule based on individual response.

Steroids and Steroid Implants

Steroids interrupt the inflammatory cascade that contributes to fluid leakage in diabetic eye disease, vein occlusion and uveitis. A straightforward intravitreal injection of triamcinolone acetonide may be repeated every one to three months, but carries a higher risk of cataract formation and raised eye pressure. For longer-acting control, tiny implants slowly release corticosteroid over months to years—Ozurdex typically lasts four to six months, while Iluvien and Yutiq implants can provide up to 36 months of therapy.

Antibiotic, Antiviral & Antifungal Injections

In sight-threatening infections like endophthalmitis or viral retinitis, systemic drugs often struggle to reach effective levels inside the eye. Intravitreal antibiotics (vancomycin, ceftazidime) and antivirals (ganciclovir, foscarnet) deliver a powerful, concentrated dose directly to the site of infection. Depending on the severity and pathogen, one or more injections may be required in quick succession until the infection is under control.

Gas Injections for Retinal Detachment

When part of the retina peels away from its underlying support, a small bubble of inert gas (SF6 or C3F8) can be injected to press the tissue back into place. The expanding bubble acts like an internal tamponade, flattening the retina and allowing natural adhesion to reform. Patients follow specific head-positioning instructions (often face-down) for one to two weeks to keep the bubble in contact with the detachment site and ensure optimal healing.

Eligibility, Contraindications & Pre-Injection Assessment

Before proceeding with intravitreal injections, a thorough assessment ensures each patient is a suitable candidate and understands the process. This evaluation centres on balancing potential benefits against risks, confirming there are no barriers to a safe procedure, and establishing a clear, informed plan of care.

Patient Selection Criteria

Not every retinal condition or patient profile warrants an intravitreal injection. Selection typically hinges on:

• Disease severity and visual impact: for example, significant macular oedema or active neovascularisation in wet AMD.
• Visual acuity thresholds: many specialists consider letters lost on the eye chart and overall functional vision.
• General health and comorbidities: uncontrolled diabetes, hypertension or clotting disorders may require optimisation first.
• Patient reliability: ongoing treatment often follows a strict schedule, so a willingness and ability to attend regular appointments is essential.

Contraindications & Precautions

Absolute contraindications include:

• Active ocular infection (e.g. conjunctivitis, keratitis) or severe intraocular inflammation.
• Known allergy to the intended medication or antiseptic agents.
• Uncontrolled systemic infection or immunosuppression.

Relative precautions cover situations such as:

• Recent myocardial infarction, stroke or thromboembolic event.
• Pregnancy or breastfeeding—certain drugs (especially anti-VEGF) lack safety data in these groups.
• Significant ocular surface disease or blepharitis that might increase infection risk.

Informed Consent Process

A robust consent discussion is the cornerstone of patient-centred care. Key elements include:

• Clear explanation of the procedure steps, expected sensations (pressure rather than pain) and typical duration (10–15 minutes).
• Review of potential side effects—from mild redness to rare complications like endophthalmitis.
• Alternatives and adjuncts (laser therapy, observation or surgery).
• Frequency of injections (loading phase, then treat-and-extend or PRN).
• An opportunity for questions, ensuring patients fully grasp risks versus benefits before signing consent.

Specialists should refer to shared decision-making checklists and outline follow-up protocols. Routine use of topical antibiotics is discouraged by Choosing Wisely Australia (RANZCO7), and maintaining a strict aseptic technique is vital as per RANZCO outpatient guidance (RANZCO4).

Pre-Injection Imaging & Tests

Baseline investigations help tailor treatment and monitor response:

• Optical coherence tomography (OCT) to quantify retinal thickness and fluid.
• Fundus photography or fluorescein angiography to map areas of leakage or neovascular growth.
• Intraocular pressure measurement, especially in eyes prone to glaucoma or when planning steroid injections.
• Systemic checks where relevant—blood glucose levels in diabetic patients or blood pressure in those with vascular risk.

With these assessments complete, injection planning proceeds with confidence, knowing each step is built on a foundation of patient safety and optimal treatment outcomes.

The Injection Procedure: Step-by-Step

Undergoing an intravitreal injection can feel daunting, but the procedure itself is efficient and carefully choreographed to ensure safety and comfort. Most patients complete the entire process—from check-in to check-out—in around 20 to 30 minutes, with the actual injection taking just 10–15 minutes. Below we break down each stage so you know exactly what to expect.

Clinic Setting & Equipment

Your injection will take place in a treatment room or minor procedure area rather than a full operating theatre. You’ll sit in a reclined, adjustable chair that tilts back to a near-horizontal position, giving your specialist clear access to the eye. On a nearby sterile tray you’ll see:

• Sterile drapes and gauze
• A small bottle of povidone-iodine solution
• A speculum to hold your eyelids open
• A selection of fine needles and syringes (usually 30–32 gauge)
• Emergency resuscitation kit, just in case

Good lighting and magnification loupes or a slit lamp ensure the doctor can visualise the injection site precisely. While it looks clinical, every piece of equipment is chosen to make the injection as quick and comfortable as possible.

Sterility & Aseptic Technique

Preventing infection is the top priority. The steps include:

1. Verifying your identity and checking for allergies.
2. Cleansing the eye and surrounding skin with povidone-iodine, an antiseptic known to eliminate most ocular surface bacteria.
3. Draping the area with a sterile field, then donning a mask and sterile gloves.
4. Placing a disposable eyelid speculum to keep your eyelids from blinking during the injection.

Routine use of topical antibiotics before or after the injection is not recommended by RANZCO Choosing Wisely Australia (RANZCO4). Meticulous aseptic technique—with povidone-iodine as the primary defence—has been shown to keep infection rates extremely low.

Anaesthesia & Pain Control

Most patients feel little more than mild pressure. To ensure you’re comfortable:

• Anaesthetic drops or gel are applied to numb the eye surface.
• In some cases, a tiny subconjunctival injection of local anaesthetic is given for extra numbness.
• After application, there’s a brief pause (one to two minutes) to allow full effect.

We also recommend a few simple tips to calm nerves: practise slow, steady breathing, focus on a fixed point on the ceiling, or listen to soft music if available. Our team will chat with you throughout to keep you informed and relaxed.

Injection Technique

With the eye numbed and prepped, your doctor will:

1. Ask you to look in a specific direction—often down and in or up and out—so the intended quadrant is exposed.
2. Measure approximately 3–4 mm behind the limbus (the junction of cornea and sclera) to avoid the lens and retina.
3. Advance a 30–32 gauge needle into the pars plana and inject 0.05 mL of medication into the vitreous cavity.
4. Withdraw the needle, then gently clean away any excess solution.

There’s no routine requirement for post-injection antibiotic drops, given the strict aseptic measures already taken. A single drop of lubricant or antibiotic ointment may be applied at the doctor’s discretion.

Patient Experience & Duration

Most people describe the injection as a brief pressing or pushing sensation rather than sharp pain. The speculum may feel slightly uncomfortable, but it’s removed immediately afterwards. Once the needle is out, the eye is wiped clean and you’re free to sit up.

In total, you’ll spend around 10–15 minutes in the chair, with a few extra minutes allotted for consent and post-procedure instructions. Shortly after, you’ll be able to walk out unassisted, ready to carry on with light activities for the remainder of the day.

Through each step, the focus remains on combining meticulous safety protocols with patient comfort—so you can get back to seeing life clearly as quickly as possible.

Side Effects & Complications

No medical procedure is completely risk-free, and while intravitreal (eyeball) injections are generally safe, it helps to know what to expect. Most patients experience only mild, temporary reactions. A small proportion will face more serious ocular or systemic issues that demand prompt attention. By recognising common side effects and understanding how rare complications can be prevented or caught early, you’ll feel more reassured throughout your treatment journey.

Common, Mild Reactions

It’s perfectly normal to notice minor after-effects in the hours and days following an injection. These usually resolve without intervention:

• Conjunctival haemorrhage: a bright red spot on the white of the eye, often fading within 5–10 days.
• Surface irritation: a gritty or scratchy feeling caused by the antiseptic (povidone-iodine) used to prep the eye.
• Floaters or air bubbles: small specks drifting in your vision, reflecting either vitreous movement or residual air from the syringe.

Most people manage these symptoms with preservative-free artificial tears and mild analgesics (paracetamol). If discomfort lingers beyond 48 hours, let your specialist know.

Serious Ocular Complications

There is a very low—but non-zero—risk of sight-threatening complications. Incidence rates from optometry literature (see Optometry Australia’s open-access articles) and retinal specialist series indicate:

• Endophthalmitis (intraocular infection): 0.02–0.09% of injections.
• Retinal detachment: under 0.01%.
• Vitreous haemorrhage (internal bleeding): approximately 0.05–0.1%.
• Intraocular pressure (IOP) spike: transient rises common, persistent spikes more likely in glaucoma patients.

These figures underscore the importance of swift action should you notice warning signs. Contact your ophthalmologist immediately if you experience any of the following after the first day:

• Sharp or worsening pain in the eye
• A sudden increase in floaters or new flashes of light
• Significant drop in vision
• Severe light sensitivity

Early diagnosis and treatment are crucial to preserving vision.

Systemic Risks

Although intravitreal drugs are delivered directly into the eye, trace amounts can enter systemic circulation. Rare systemic events include:

• Arterial thromboembolism (stroke, heart attack), with anti-VEGF therapies showing rates similar to untreated populations in large trials.
• Hypersensitivity reactions, such as rash or itching, to either medication or antiseptic.

Your doctor will review your cardiovascular history and allergy profile before recommending treatment, ensuring the overall benefits outweigh any systemic risk.

Prevention & Early Detection

Keeping complications to a minimum begins before the needle ever touches your eye:

1. Strict aseptic technique: cleansing with povidone-iodine, using sterile gloves, drapes and speculum, and avoiding routine topical antibiotics (per Choosing Wisely Australia (RANZCO4)).
2. Patient education: clear instructions on post-injection care—no eye rubbing, no swimming or heavy lifting for 24–48 hours.
3. Urgent access: direct contact details for reporting new or worsening symptoms.
4. Scheduled follow-up: intraocular pressure checks and imaging (OCT) to monitor treatment response and catch issues early.

By working together with your eye care team and staying alert to both mild and serious signs, you’ll help maintain a safe and effective treatment plan.

Recovery, Aftercare & Follow-Up

Once the injection is complete, your eye care journey continues with a carefully planned aftercare routine. Most patients head home within minutes, but the hours and days that follow are equally important for a smooth recovery and optimal treatment outcome. Below, you’ll find guidance on immediate care, activity recommendations, comfort measures and the schedule for follow-up visits.

Immediate Post-Injection Care

Right after the injection, your specialist will gently clean any residual antiseptic from the eye surface and may apply a drop of lubricant or a thin layer of antibiotic ointment—though routine antibiotic use isn’t usually required. You’ll sit up slowly and rest for a few minutes to ensure there’s no immediate discomfort or dizziness. An eye patch is rarely needed, but if your eyelid feels heavy or you’re sensitive to light, a loose, breathable shield can offer temporary relief.

Activity Restrictions & Rest Advice

During the first 24 to 48 hours:

• Avoid getting water, soap or shampoo in the treated eye—no swimming, hot tubs or saunas.
• Steer clear of dusty or smoky environments that might irritate the ocular surface.
• Hold off on heavy lifting, strenuous exercise or bending at the waist, as these can spike intraocular pressure.
• Do not rub or press on the eye; if you need to clean around it, use a fresh, damp cloth with gentle dabs.

Resuming light activities—such as walking, reading or desk work—is fine, provided you steer clear of anything that risks eye trauma or contamination.

Comfort Measures

Mild irritation and a gritty feeling are common after intravitreal treatment. To ease discomfort:

• Instil preservative-free artificial tears several times a day to soothe the surface and wash away any lingering antiseptic.
• Take simple pain relief like paracetamol if you experience mild ache or soreness around the eye.
• Apply a cool, clean compress (a wrapped ice pack or chilled face cloth) over the closed eyelid for five to ten minutes to reduce surface redness.

If you notice persistent pain, a dramatic increase in floaters or any vision changes beyond mild blurring, contact your ophthalmologist without delay.

Follow-Up Visits & Monitoring

A review appointment is typically scheduled four to six weeks after your injection. During this visit, your specialist will:

• Measure your visual acuity and check intraocular pressure.
• Perform optical coherence tomography (OCT) to assess retinal thickness and fluid levels.
• Examine the injection site and overall eye health under magnification.
• Decide whether to continue with the next dose, adjust the interval between injections or alter your treatment plan.

Ongoing monitoring—combining clinical examination and imaging—ensures that the therapy is having the desired effect and helps detect any late-onset complications early. Keeping these appointments is crucial for long-term success and maintaining the best possible vision.

Treatment Regimens & Long-Term Management

Managing retinal conditions with eyeball injections often extends beyond a single appointment. A structured regimen helps maintain disease control while minimising both treatment burden and potential risks. Below, we outline the most common approaches to scheduling injections, how specialists tailor therapy over time, considerations around long-term safety, and a glimpse at innovations on the horizon.

Standard Injection Schedules

Most anti-VEGF and steroid treatments begin with an initial “loading phase” to quickly suppress disease activity. For anti-VEGF agents, this usually means one injection per month for three to six months. Once the retina stabilises, three key pathways are available:

• Treat-and-Extend: Gradually lengthening the interval between injections (by two-week increments) as long as the retina remains dry on optical coherence tomography (OCT).
• Pro Re Nata (PRN): Providing injections only when signs of fluid or new bleeding recur, as determined at regular follow-up visits.
• Fixed Dosing: Maintaining a constant interval (for instance, every eight weeks) if treat-and-extend or PRN approaches are unsuitable.

Steroid implants follow a similar logic but on a longer timetable. A dexamethasone implant (Ozurdex) may be replaced every four to six months, while fluocinolone devices (Iluvien, Yutiq) can last up to 36 months before the next injection is needed.

Monitoring & Adjustment

Regular assessment is the cornerstone of any long-term injection plan. At each visit, your specialist will:

1. Measure visual acuity and check intraocular pressure.
2. Perform OCT to quantify retinal thickness and detect subtle fluid pockets.
3. Review any symptoms you’ve experienced—floaters, flashes, soreness or changes in vision.

Based on these findings, your doctor decides whether to maintain the current interval, shorten it (if there’s renewed swelling), or lengthen it further. This dynamic, data-driven process ensures you receive treatment exactly when needed—no more, no less.

Long-Term Safety

Repeated intravitreal injections have an excellent safety record, but vigilance remains essential. Over many years of therapy, potential concerns include:

• Endophthalmitis: Although rare (0.02–0.09% per injection), strict aseptic technique and patient education on warning signs are vital.
• Intraocular Pressure (IOP): Steroid injections carry a higher risk of IOP elevation. Regular pressure checks and early treatment of glaucoma help prevent optic nerve damage.
• Cataract Formation: Particularly with steroids, the likelihood of cataract increases, often addressed surgically if vision becomes affected.
• Treatment Fatigue: Attending frequent appointments can be challenging. Clear communication, flexible scheduling and support services improve patient retention and adherence.

By balancing benefits against these risks—and by adjusting therapy protocols as your eye health evolves—your specialist aims to preserve vision safely over the long haul.

Emerging Therapies

Research continues to refine how we deliver and sustain medication in the eye. Among promising developments are:

• Long-Acting Anti-VEGF Agents: New molecules with extended durability may reduce injection frequency to every three or four months.
• Port Delivery Systems: Implantable reservoirs that release ranibizumab gradually, requiring refill procedures rather than full injections.
• Gene Therapy: Techniques that prompt retinal cells to produce their own anti-VEGF proteins, potentially offering multi-year treatment from a single dose.

While these innovations progress through clinical trials, conventional intravitreal injections remain the gold standard for preserving vision in wet AMD, diabetic eye disease and other retinal disorders. Staying informed about emerging options ensures you and your specialist can plan the best long-term strategy for your eyesight.

Cost & Funding Options in Australia

Understanding the financial side of intravitreal (eyeball) injections helps you plan treatment without any surprises. Costs can vary by clinic, medication choice and your level of cover. Below is a guide to typical out-of-pocket expenses, how Medicare and private health insurance apply, and strategies to minimise your costs.

Out-of-Pocket Costs

In a private Sydney practice, the total fee for an intravitreal injection session—including specialist consultation, the procedure itself and a follow-up review—typically ranges from AUD 400 to AUD 650. After claiming the Medicare rebate (see below), your personal expense is often in the vicinity of AUD 200–400 per visit. Factors influencing the final amount include:

• The specific anti-VEGF or steroid drug used
• Complexity of your eye condition and need for longer chair-time
• Specialist fee schedule and any additional nursing or imaging services

Always request a written estimate before booking, so you know exactly what to expect.

Medicare & Private Health Cover

Most intravitreal injections performed outside a hospital attract Medicare Benefit Schedule (MBS) item 42778 (injection of a therapeutic substance into the vitreous body). The current Medicare rebate for item 42778 is around AUD 263. You can claim this rebate on the spot using your Medicare card or via a later online claim.

Private health insurance may further reduce your gap payment. Depending on your policy:

• “No-gap” arrangements mean the Medicare rebate completely covers the specialist’s fee, leaving you with zero out-of-pocket cost.
• If a gap remains, it can range from AUD 50 to AUD 200 per injection, depending on your fund’s restrictions and the clinic’s billing policy.

Before treatment, confirm with your insurer the level of cover for intravitreal procedures and whether any pre-authorisation is required.

“No-Gap” & Financial Assistance

Some ophthalmology clinics enter into “no-gap” agreements with private insurers. In these cases, insured patients pay nothing beyond the Medicare rebate, provided they meet the fund’s eligibility criteria (for example, having hospital cover with no exclusions for eye procedures).

In addition, certain high-cost medications may be available through patient access programmes run by pharmaceutical companies. These can reduce or waive co-payments for eligible individuals. Ask your ophthalmologist or practice manager whether any such schemes apply to your treatment.

Cost-Saving Tips

• If you hold a Pensioner Concession Card or Commonwealth Seniors Health Card, you may qualify for higher Medicare rebates under the Extended Medicare Safety Net.
• Public hospital eye clinics often provide subsidised intravitreal injections for concession card holders, though waiting lists can apply.
• Enquire about package deals if you anticipate a series of injections—some practices offer discounted rates for multi-visit treatment plans.
• Always ask for an itemised quote and confirm rebate amounts before your first injection, so there are no unexpected charges.

By combining Medicare rebates, private health cover and available assistance programmes, most patients can manage the cost of intravitreal injections in Australia while maintaining access to world-class retinal care.

Frequently Asked Questions About Eyeball Injections

Below are answers to some of the most common questions patients have about intravitreal (eyeball) injections. We hope this helps clarify what to expect and eases any remaining concerns.

Do Eyeball Injections Hurt?

Most people report feeling only mild pressure rather than sharp pain. Before the injection, your eye is numbed with drops or gel, and sometimes a tiny subconjunctival (under-the-conjunctiva) anaesthetic is also used. By the time the needle enters through the pars plana, the surface of your eye will be completely numb. You might feel a brief pushing sensation, but any discomfort usually subsides immediately after the injection.

How Long Does an Eye Injection Take to Heal?

Healing is generally swift.

• A small subconjunctival haemorrhage (a red spot on the white of the eye) can appear at the injection site and typically fades within 5–10 days.
• Mild surface irritation from the antiseptic prep may cause a gritty sensation for 24–48 hours.

Most patients see these minor effects resolve naturally within a week. If redness, pain or vision changes linger beyond that, let your specialist know right away.

Should I Rest After an Eye Injection?

Light rest is recommended in the first 24–48 hours:

• Avoid getting water or shampoo in your treated eye—no swimming, hot tubs or face-washing over the eye.
• Steer clear of dusty or smoky environments, strenuous exercise, heavy lifting and bending at the waist.
• Do not rub or press on the eye; instead, dab around it gently if you need to clean the surrounding skin.

You can resume normal, low-impact activities—reading, desk work or watching TV—almost immediately, as long as you follow these simple precautions.

When Will I Notice Vision Improvement?

The time to vision improvement varies by condition:

• In wet AMD, many patients notice reduced distortion or clearer vision after one to two monthly injections, with more pronounced gains around the three-month mark.
• For diabetic macular oedema or retinal vein occlusion, fluid often begins to clear on optical coherence tomography (OCT) within weeks, and functional vision improvements follow soon after.

Individual responses differ. Some people see subtle changes within days, while others require several loading doses before noticing a real difference. Your specialist will use imaging and vision tests at follow-up visits to track progress and adjust the treatment plan.

How Much Do Eye Injections Cost in Australia?

Out-of-pocket expenses depend on the medication used, your specialist’s fees and your level of cover. In a private Sydney practice, the total fee per injection visit usually falls between AUD 400 and 650. After claiming the Medicare rebate (MBS item 42778 currently rebates around AUD 263), most patients pay roughly AUD 200–400 per session.

If you have private health insurance, you may qualify for a “no-gap” arrangement—meaning the Medicare rebate covers the entire specialist fee. Pensioners and concession-card holders might access higher rebates under the safety-net scheme, and some public hospital clinics offer subsidised treatment based on clinical need. Always ask your clinic for a detailed quote and check with your insurer before booking.

Next Steps for Your Intravitreal Injection Journey

Deciding on intravitreal injections can feel like a big step, but having the right support makes all the difference. Start by booking an appointment with a trusted ophthalmologist—ideally one who takes the time to review your individual eye health, answer your questions and explain every aspect of the treatment plan. Bring a list of concerns—whether it’s about the procedure itself, potential side effects or how the injections fit into your lifestyle—so you leave the consultation feeling informed and confident.

Early intervention is key when it comes to retinal conditions. Catching and treating issues such as macular degeneration, diabetic macular oedema or vein occlusion before significant damage occurs offers the best chance of preserving vision. Your ophthalmologist will work with you to establish a personalised schedule—balancing treatment efficacy with convenience—so you can maintain the activities that matter most.

At Bright Sight Eye Specialists, Dr Rahul Dubey and the team combine advanced technology with a patient-centred approach. If you’re ready to explore whether eyeball injections are right for you, our friendly staff are here to help. Visit Bright Sight Eye Specialists to learn more about our services or to book your initial consultation today. Call us on 9128 0888.